Propella Site Layouts-14

the control center

Focused direction, dedicated purpose and lifetimes of relevant experience.

the hearts & minds

Leadership with direction, purpose and lifetimes of experience that encompass all aspects of pharmaceutical development through commercialization.

William Moore, PhD
President, Chief Executive Officer, and Board Director

William Moore, PhD
A business and scientific leader in pharmaceutical and biotechnology R&D, Dr. Moore has devoted his 30-year career to championing new chemical entities from discovery to the clinic (navigating the pharmaceutical industry ‘Valley of Death’) for the treatment of asthma, osteoporosis, inflammatory diseases, and with an emphasis on oncology. Before leading the spinout of Propella from Vizuri Health Sciences (VHS) in 2020, Dr. Moore held key positions of increasing responsibility at the Merrell Dow Research Institute, and Axys Pharmaceuticals, including CSO responsibilities at Locus Pharmaceuticals and Viamet Pharmaceuticals, and CEO and Director responsibilities at Innocrin Pharmaceuticals and VHS. Dr. Moore has dep experience with fundraising, corporate strategy, new business development, management of external alliances, intellectual property strategy, and all aspects of R&D and technology innovation.

Dr. Moore holds a BS in chemistry from Southeastern Massachusetts University, a PhD in chemistry from Brown University and, prior to joining the pharmaceutical industry, was a Winston Fellow and Assistant Professor in Biochemistry at Cornell University Medical College.

George Cox, PhD, JD 
Chief Legal Officer & Corporate Secretary

George Cox, PhD, JD
Dr. George Cox brings more than 30 years of combined science and legal experience to Propella Therapeutics.  Prior to joining Propella, Dr. Cox was in private practice at IP & Business Law Counseling, LLC, Miles & Stockbridge PC, and Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.  Before attending law school, he enjoyed a career as a biomedical scientist at the National Cancer Institute and a professor of pharmacology and molecular & cell biology at the Uniformed Services University of the Health Sciences, F. Edward Hebert School of Medicine.  He’s authored more than 70 publications in diverse scientific disciplines including pharmacology, immunology, biochemistry, and cell and molecular biology.

Dr. Cox earned his BA degree in chemistry and zoology from Ohio Wesleyan University, his PhD degree in pharmacology from The Ohio State University College of Medicine, and his JD degree from The American University Washington College of Law. 

Brendan M. Griffin
Chief Financial Officer

Brendan Griffin, MBA, MSPPM
As Chief Financial Officer at Propella, Brendan has focused on strategic and operational activities, including research & development strategy, business development, strategic financing, clinical operations, and administration. Prior to becoming a biotechnology executive, Brendan spent the bulk of his career as an investment banker providing capital markets and advisory services to clients across North America, Europe, and Asia. He was a senior member of the biotechnology investment banking team at Leerink Partners (formerly SVB Leerink), where he completed over 100 transactions, including more than 20 IPOs.

Brendan holds a Master of Business Administration degree from Carnegie Mellon University’s Tepper School of Business, a Master of Public Policy Management degree from Carnegie Mellon University’s Heinz School of Public Policy, and a B.S. from Elon University.

Matthew Sharp, PhD  
Vice President, Product Development

Matthew Sharp, PhD
Dr. Matt Sharp brings more than 25 years of pharmaceutical product development experience to Propella Therapeutics.  Prior to joining Propella he was Senior Director of Chemistry, Manufacturing and Controls (CMC) at Innocrin Pharmaceuticals.  Previously, he held a number of positions of increasing responsibility with GlaxoSmithKline (GSK), most recently serving as U.S. Head of Process Robustness and 2nd Generation, Active Pharmaceutical Ingredients (APIs).  In these roles he was responsible for the development and manufacture of APIs as well as finished drug products.  He has extensive experience in the manufacturing of drug products, research and development, process development, cGMP manufacturing, analytical development and quality systems.

In preparation for his pharmaceutical career, Matt received a BSc degree in Chemistry from Sheffield City (England) Polytech, a MSc in Organic Chemistry from the University of Waterloo (Canada), a PhD in Organic Chemistry from the University of California, Irvine, and then trained as postdoctoral research fellow at the University of California, Berkeley.